Catalyst Event
Pfizer Inc (PFE) · Other
From Akros U.S. High Dividend Index (AUHD20)
3/17/2026, 12:00:00 AM
Announced positive topline results on March 17, 2026, from the Phase 2 study of atirmociclib, a next-generation CDK4 inhibitor, for second-line metastatic breast cancer.
Korean Translation
2026년 3월 17일, 2차 전이성 유방암 치료를 위한 차세대 CDK4 억제제 아티르모시클립(atirmociclib)의 2상 임상에서 긍정적인 탑라인 결과를 발표함.
Related Recent Events
Reynolds Consumer Products Inc (REYN) · Earnings Release
Q1 2026 earnings release and annual stockholder meeting scheduled. Analysts forecast EPS of approximately $0.24. 5% price impact estimated due to typical earnings volatility; scheduled.
4/29/2026, 12:00:00 AM
Antero Midstream Corp (AM) · Earnings Release
Q1 2026 earnings release is scheduled for April 29, 2026; as it is a routine announcement, low impact is expected.
4/29/2026, 12:00:00 AM
Verizon Communications Inc (VZ) · Earnings Release
Verizon is scheduled to report its Q1 2026 earnings results on April 27, 2026, before market open; estimated Medium importance as earnings typically drive >5% price impact, scheduled.
4/27/2026, 12:00:00 AM
Chevron Corp (CVX) · Earnings Release
Chevron is scheduled to report its Q1 2026 earnings on April 24, 2026; analysts forecast an EPS of $1.72, scheduled.
4/24/2026, 12:00:00 AM
First Hawaiian Inc (FHB) · Earnings Release
First quarter 2026 earnings release is scheduled for April 22, 2026. Analysts forecast earnings of $0.53 per share. This is estimated to have a medium price impact of at least 5% as a major quarterly update, which is forecasted and scheduled.
4/22/2026, 12:00:00 AM
Bank of Hawaii Corp (BOH) · Earnings Release
Bank of Hawaii Corporation's first-quarter 2026 earnings release is scheduled. A medium market impact is estimated.
4/20/2026, 12:00:00 AM